C3肾小球病的治疗或迎重大突破!Iptacopan显示出希望

2020-10-27 Allan MedSci原创

在一项II期研究中,诺华的肾脏疾病候选药物iptacopan的显示出治疗C3肾小球病的希望。

C3肾小球病(C3G)是新提出的肾脏疾病分类, 是指一些罕见的肾炎, 包括致密物沉积病、C3肾小球肾炎和CFHR5肾病等。C3肾小球病具有相同的病因, 即补体旁路途径的异常调节, 有时伴基因缺陷或自身抗体异常。

在一项II期研究中,诺华的肾脏疾病候选药物iptacopan的显示出治疗C3肾小球病的希望。结果显示,与12例患者的基线值相比,该药物在12周后可显著降低49%的蛋白尿(蛋白尿提示肾脏中存在炎症)。这些数据还强调了iptacopan能够强烈和特异性地抑制替代补体途径,从而针对该疾病的根本原因,并可能为C3G患者提供急需的治疗选择。

欧洲药品管理局(EMA)已授予iptacopan治疗C3G的PRIME称号,EMA还授予了iptacopan治疗IgA肾病(IgAN)的孤儿药称号。除了C3G以外,iptacopan还用于许多其他肾脏疾病,如非典型溶血性尿毒症综合征和膜性肾病。

 

原始出处:

http://www.pharmatimes.com/news/novartis_rare_renal_disease_candidate_shows_promise_in_phase_ii_1354811

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1951903, encodeId=2c08195190314, content=<a href='/topic/show?id=1fcb39098a' target=_blank style='color:#2F92EE;'>#C3肾小球病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3909, encryptionId=1fcb39098a, topicName=C3肾小球病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Fri Dec 25 03:04:21 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033728, encodeId=73f22033e28d9, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Dec 23 23:04:21 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976538, encodeId=b28d9e6538cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Thu Jun 24 15:25:31 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669149, encodeId=af63166914962, content=<a href='/topic/show?id=0aeb1e075c1' target=_blank style='color:#2F92EE;'>#TACO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17075, encryptionId=0aeb1e075c1, topicName=TACO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=010026501637, createdName=lujian, createdTime=Tue Oct 05 15:04:21 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894956, encodeId=29ae894956bf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2d5429609, createdName=ms1000002114994444, createdTime=Tue Oct 27 22:51:42 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894946, encodeId=72338949461a, content=很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335418832, createdName=ms9000001913660756, createdTime=Tue Oct 27 22:17:08 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894942, encodeId=01be894942ba, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Oct 27 22:12:56 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1951903, encodeId=2c08195190314, content=<a href='/topic/show?id=1fcb39098a' target=_blank style='color:#2F92EE;'>#C3肾小球病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3909, encryptionId=1fcb39098a, topicName=C3肾小球病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Fri Dec 25 03:04:21 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033728, encodeId=73f22033e28d9, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Dec 23 23:04:21 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976538, encodeId=b28d9e6538cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Thu Jun 24 15:25:31 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669149, encodeId=af63166914962, content=<a href='/topic/show?id=0aeb1e075c1' target=_blank style='color:#2F92EE;'>#TACO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17075, encryptionId=0aeb1e075c1, topicName=TACO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=010026501637, createdName=lujian, createdTime=Tue Oct 05 15:04:21 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894956, encodeId=29ae894956bf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2d5429609, createdName=ms1000002114994444, createdTime=Tue Oct 27 22:51:42 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894946, encodeId=72338949461a, content=很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335418832, createdName=ms9000001913660756, createdTime=Tue Oct 27 22:17:08 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894942, encodeId=01be894942ba, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Oct 27 22:12:56 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-12-23 grace5700
  3. [GetPortalCommentsPageByObjectIdResponse(id=1951903, encodeId=2c08195190314, content=<a href='/topic/show?id=1fcb39098a' target=_blank style='color:#2F92EE;'>#C3肾小球病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3909, encryptionId=1fcb39098a, topicName=C3肾小球病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Fri Dec 25 03:04:21 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033728, encodeId=73f22033e28d9, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Dec 23 23:04:21 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976538, encodeId=b28d9e6538cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Thu Jun 24 15:25:31 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669149, encodeId=af63166914962, content=<a href='/topic/show?id=0aeb1e075c1' target=_blank style='color:#2F92EE;'>#TACO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17075, encryptionId=0aeb1e075c1, topicName=TACO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=010026501637, createdName=lujian, createdTime=Tue Oct 05 15:04:21 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894956, encodeId=29ae894956bf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2d5429609, createdName=ms1000002114994444, createdTime=Tue Oct 27 22:51:42 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894946, encodeId=72338949461a, content=很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335418832, createdName=ms9000001913660756, createdTime=Tue Oct 27 22:17:08 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894942, encodeId=01be894942ba, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Oct 27 22:12:56 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2021-06-24 12192b1am98暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1951903, encodeId=2c08195190314, content=<a href='/topic/show?id=1fcb39098a' target=_blank style='color:#2F92EE;'>#C3肾小球病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3909, encryptionId=1fcb39098a, topicName=C3肾小球病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Fri Dec 25 03:04:21 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033728, encodeId=73f22033e28d9, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Dec 23 23:04:21 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976538, encodeId=b28d9e6538cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Thu Jun 24 15:25:31 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669149, encodeId=af63166914962, content=<a href='/topic/show?id=0aeb1e075c1' target=_blank style='color:#2F92EE;'>#TACO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17075, encryptionId=0aeb1e075c1, topicName=TACO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=010026501637, createdName=lujian, createdTime=Tue Oct 05 15:04:21 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894956, encodeId=29ae894956bf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2d5429609, createdName=ms1000002114994444, createdTime=Tue Oct 27 22:51:42 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894946, encodeId=72338949461a, content=很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335418832, createdName=ms9000001913660756, createdTime=Tue Oct 27 22:17:08 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894942, encodeId=01be894942ba, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Oct 27 22:12:56 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2021-10-05 lujian
  5. [GetPortalCommentsPageByObjectIdResponse(id=1951903, encodeId=2c08195190314, content=<a href='/topic/show?id=1fcb39098a' target=_blank style='color:#2F92EE;'>#C3肾小球病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3909, encryptionId=1fcb39098a, topicName=C3肾小球病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Fri Dec 25 03:04:21 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033728, encodeId=73f22033e28d9, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Dec 23 23:04:21 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976538, encodeId=b28d9e6538cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Thu Jun 24 15:25:31 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669149, encodeId=af63166914962, content=<a href='/topic/show?id=0aeb1e075c1' target=_blank style='color:#2F92EE;'>#TACO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17075, encryptionId=0aeb1e075c1, topicName=TACO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=010026501637, createdName=lujian, createdTime=Tue Oct 05 15:04:21 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894956, encodeId=29ae894956bf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2d5429609, createdName=ms1000002114994444, createdTime=Tue Oct 27 22:51:42 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894946, encodeId=72338949461a, content=很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335418832, createdName=ms9000001913660756, createdTime=Tue Oct 27 22:17:08 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894942, encodeId=01be894942ba, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Oct 27 22:12:56 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-10-27 ms1000002114994444

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1951903, encodeId=2c08195190314, content=<a href='/topic/show?id=1fcb39098a' target=_blank style='color:#2F92EE;'>#C3肾小球病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3909, encryptionId=1fcb39098a, topicName=C3肾小球病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Fri Dec 25 03:04:21 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033728, encodeId=73f22033e28d9, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Dec 23 23:04:21 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976538, encodeId=b28d9e6538cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Thu Jun 24 15:25:31 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669149, encodeId=af63166914962, content=<a href='/topic/show?id=0aeb1e075c1' target=_blank style='color:#2F92EE;'>#TACO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17075, encryptionId=0aeb1e075c1, topicName=TACO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=010026501637, createdName=lujian, createdTime=Tue Oct 05 15:04:21 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894956, encodeId=29ae894956bf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2d5429609, createdName=ms1000002114994444, createdTime=Tue Oct 27 22:51:42 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894946, encodeId=72338949461a, content=很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335418832, createdName=ms9000001913660756, createdTime=Tue Oct 27 22:17:08 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894942, encodeId=01be894942ba, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Oct 27 22:12:56 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-10-27 ms9000001913660756

    很受益

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1951903, encodeId=2c08195190314, content=<a href='/topic/show?id=1fcb39098a' target=_blank style='color:#2F92EE;'>#C3肾小球病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3909, encryptionId=1fcb39098a, topicName=C3肾小球病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c950224, createdName=hjwang79, createdTime=Fri Dec 25 03:04:21 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033728, encodeId=73f22033e28d9, content=<a href='/topic/show?id=fc431e0708f' target=_blank style='color:#2F92EE;'>#TAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17070, encryptionId=fc431e0708f, topicName=TAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Wed Dec 23 23:04:21 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976538, encodeId=b28d9e6538cf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a272265480, createdName=12192b1am98暂无昵称, createdTime=Thu Jun 24 15:25:31 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669149, encodeId=af63166914962, content=<a href='/topic/show?id=0aeb1e075c1' target=_blank style='color:#2F92EE;'>#TACO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17075, encryptionId=0aeb1e075c1, topicName=TACO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=010026501637, createdName=lujian, createdTime=Tue Oct 05 15:04:21 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894956, encodeId=29ae894956bf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a2d5429609, createdName=ms1000002114994444, createdTime=Tue Oct 27 22:51:42 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894946, encodeId=72338949461a, content=很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a335418832, createdName=ms9000001913660756, createdTime=Tue Oct 27 22:17:08 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894942, encodeId=01be894942ba, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Tue Oct 27 22:12:56 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-10-27 wxl882001

    了解

    0

相关资讯

诺华2019年财报:Consetyx销售额居首,基因治疗未来可期

诺华于近日公布了2019年财报,公司全年实现净销售额474.75亿美元,同比增长6%(以固定汇率计算为9%)。其中制药事业部的Consetyx(35.53亿美元,+25%),Entresto(17.26亿美元,+68%)和Zolgensma(3.61亿美元),肿瘤事业部的Promacta/Revolade(14.16亿美元,+21%),Kisqali(4.8亿美元,+104%)和Lutathe

英国首位患者在NHS内接受诺华的Luxturna基因疗法治疗先天性黑蒙病

英国国家医疗服务体系(NHS)表示,作为其长期计划的一部分,诺华公司的Luxturna(voretigene neparvovec)基因疗法将用于首位遗传性视网膜疾病-莱伯先天性黑蒙病(LCA)患者以恢复视力。

诺华的MET抑制剂卡马替尼治疗非小细胞肺癌,获得FDA授予优先审查

诺华制药宣布,美国食品药品监督管理局(FDA)接受了MET抑制剂卡马替尼(INC280)的新药申请(NDA)并给予了优先审查,用于一线治疗和先前治疗过的局部晚期或转移性MET外显子14跳跃(METex14)突变的非小细胞肺癌(NSCLC)患者。

2020 Q1各大药企收入排名,强生,罗氏,诺华,默沙东,辉瑞,礼来,阿斯利康......

4月份,强生,礼来,GSK,辉瑞、诺华、默沙东相继发布了2020年第一季度财报。在疫情的笼罩之下,今年注定是不平凡的一年。而对于跨国药企而言,其开年业绩就上演了“王座更迭”的戏

诺华的抗血管内皮生长因子(VEGF)单抗Beovu获欧盟批准,用于治疗年龄相关的湿性黄斑变性

诺华公司宣布其抗血管内皮生长因子(VEGF)单抗Beovu(brolucizumab)已获得欧洲委员会(EC)的批准,用于治疗与年龄相关的湿性黄斑变性(AMD)。

诺华与英国NHS联合,以快速推进胆固醇PCSK9的基因干扰药物inclisiran

诺华与英国国家医疗服务体系(NHS)建立了新的合作伙伴关系,该合作将使患者更快地获得其开创性的降低胆固醇药物inclisiran,诺华以97亿美元收购了开发该药物的Medicines公司。

拓展阅读

小小“泳道”,大展神通——浆细胞病导致C3肾小球病1例

从最初诊断为肾病综合征,到发现单克隆免疫球蛋白血症、浆细胞病、C3肾小球病,再到最终确诊MGRS。

APL-2获得FDA的孤儿药物认定用于治疗C3肾小球病

Apellis是一家临床阶段的生物制药公司,专注于通过抑制补体系统开发治疗疾病的新型疗法,近日宣布其C3补体抑制剂APL-2已被FDA授予孤儿药物认定用于治疗C3肾小球病。